SAN

84.81

-0.81%↓

MRK1

118.8

-0.92%↓

SHL.DE

42.59

+0.28%↑

ARGX

793.2

+0.43%↑

PHIA

22.72

-6.12%↓

SAN

84.81

-0.81%↓

MRK1

118.8

-0.92%↓

SHL.DE

42.59

+0.28%↑

ARGX

793.2

+0.43%↑

PHIA

22.72

-6.12%↓

SAN

84.81

-0.81%↓

MRK1

118.8

-0.92%↓

SHL.DE

42.59

+0.28%↑

ARGX

793.2

+0.43%↑

PHIA

22.72

-6.12%↓

SAN

84.81

-0.81%↓

MRK1

118.8

-0.92%↓

SHL.DE

42.59

+0.28%↑

ARGX

793.2

+0.43%↑

PHIA

22.72

-6.12%↓

SAN

84.81

-0.81%↓

MRK1

118.8

-0.92%↓

SHL.DE

42.59

+0.28%↑

ARGX

793.2

+0.43%↑

PHIA

22.72

-6.12%↓

Home・Aktien・Pharming Group NV

P
Pharming Group NV

Open

1.416 4.12

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.357

Max

1.421

Schlüsselkennzahlen
By Trading Economics
Einkommen	2.9M 7.5M
Verkäufe	4.1M 97M
EPS	0.009
Gewinnspanne	7.758
Angestellte	404

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-51M 946M
Vorheriger Eröffnungskurs	-2.7
Vorheriger Schlusskurs	1.416

Pharming Group NV Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

3. Dez. 2025, 23:21 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

3. Dez. 2025, 23:14 UTC

Akquisitionen, Fusionen, Übernahmen

EQB to Buy PC Financial From Loblaw for About $573.5 Million

3. Dez. 2025, 22:01 UTC

Wichtige Markttreiber

Costco Wholesale Reports Higher Monthly Sales

3. Dez. 2025, 21:38 UTC

Ergebnisse

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

3. Dez. 2025, 23:59 UTC

Market Talk

Australian Coal Prices Seen Having Recovered Well -- Market Talk

3. Dez. 2025, 23:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3. Dez. 2025, 23:49 UTC

Market Talk

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

3. Dez. 2025, 23:49 UTC

Market Talk

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

3. Dez. 2025, 23:13 UTC

Market Talk

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

3. Dez. 2025, 23:10 UTC

Ergebnisse

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

3. Dez. 2025, 23:08 UTC

Market Talk

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

3. Dez. 2025, 23:06 UTC

Akquisitionen, Fusionen, Übernahmen

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

3. Dez. 2025, 22:59 UTC

Akquisitionen, Fusionen, Übernahmen

EQB to Buy PC Financial From Loblaw for About $573.5M

3. Dez. 2025, 22:45 UTC

Market Talk

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

3. Dez. 2025, 22:20 UTC

Ergebnisse

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

3. Dez. 2025, 22:19 UTC

Ergebnisse

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

3. Dez. 2025, 22:17 UTC

Ergebnisse

Salesforce Working to Add Voice to Agentforce, CEO Says

3. Dez. 2025, 22:16 UTC

Ergebnisse

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

3. Dez. 2025, 22:15 UTC

Ergebnisse

Salesforce CEO: Agentforce ARR Was $540M in 3Q

3. Dez. 2025, 22:10 UTC

Akquisitionen, Fusionen, Übernahmen

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

3. Dez. 2025, 22:09 UTC

Akquisitionen, Fusionen, Übernahmen

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

3. Dez. 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

3. Dez. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3. Dez. 2025, 21:49 UTC

Ergebnisse

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3. Dez. 2025, 21:23 UTC

Ergebnisse

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

3. Dez. 2025, 21:19 UTC

Ergebnisse

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3. Dez. 2025, 21:06 UTC

Ergebnisse

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

3. Dez. 2025, 21:04 UTC

Ergebnisse

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

3. Dez. 2025, 21:04 UTC

Ergebnisse

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

3. Dez. 2025, 21:03 UTC

Ergebnisse

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Peer-Vergleich

Kursveränderung

Pharming Group NV Prognose

Rating-Konsens

By TipRanks

0 ratings

Buy

Halten

Sell

Basierend auf 0 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Pharming Group NV – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.